Inhibition of gastric secretion by a new H2-antagonist, YM-11170 in healthy subjects

Int J Clin Pharmacol Ther Toxicol. 1984 Apr;22(4):214-7.


Oral administration of YM-11170 (5-20 mg) inhibited both basal and tetragastrin-induced gastric secretion of acid and pepsin in healthy volunteers. YM-11170 was at least 20 times more potent than cimetidine in inhibiting stimulated acid secretion. The area under the plasma concentration of YM-11170 vs time curve correlated positively to both dose and percent inhibition of acid output in response to tetragastrin. YM-11170 significantly inhibited basal and stimulated acid secretion even 10 h after a 20-mg dose. A plasma level of YM-11170 required for 50% inhibition of stimulated acid secretion was found to be 13 ng/ml. These results indicate that YM-11170 is a very potent inhibitor of gastric acid secretion and that twice daily medication of 20 mg YM-11170 is recommendable for further antisecretory studies with ulcer patients.

Publication types

  • Comparative Study

MeSH terms

  • Administration, Oral
  • Adult
  • Cimetidine / pharmacology
  • Dose-Response Relationship, Drug
  • Famotidine
  • Gastric Acid / metabolism*
  • Gastric Juice / analysis
  • Gastric Juice / drug effects
  • Gastric Juice / metabolism
  • Humans
  • Male
  • Pepsin A / metabolism*
  • Ranitidine / pharmacology
  • Thiazoles / administration & dosage
  • Thiazoles / analysis
  • Thiazoles / blood
  • Thiazoles / pharmacology*
  • Time Factors


  • Thiazoles
  • Famotidine
  • Cimetidine
  • Ranitidine
  • Pepsin A